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Letters to the EditorReply to the Editor:
All properly conducted model-
based economic evaluations should
be a synthesis of best available evi-
dence. It is important to note that eco-
nomic models need to be updated
once new evidence is available. The
methods and assumptions used in our
economic evaluation on transcatheter
aortic valve implantation (TAVI)
were appropriate because the evalua-
tion was based on the best evidence
available at the time of the analyses.
Nevertheless, evidence on TAVI has
grown rapidly in the past 2 years. We
appreciate the comments raised by
Osnabrugge and Kappetein and agree
that a reexamination of the model
with the new evidence is warranted.
Our analysis of TAVI compared
with surgical aortic valve replacement
(SAVR) grouped the patients undergo-
ing transfemoral (TF) or transapical
(TA) approach into 1 treatment arm.
The reported clinical data from the
Placement of Aortic Transcatheter
Valve (PARTNER) cohort A also
grouped these 2 different TAVI ap-
proaches to show the noninferiority
of TAVI in terms of 1-year mortality.
This was based on a sample size cal-
culation of 650 patients at approxi-
mately 85% power.1 The stratified
clinical event rates provided in the
Supplementary Appendix were not
appropriate to use because of the
lack of statistical power. It was esti-
mated that 450 patients would need
to undergo TF placement to show non-
inferiority of TAVI compared with
SAVR at 85% power; however, only
244 patients were assigned to TF
placement in the trial. It was therefore
necessary to use utility values derived
from the New York Heart Association
functional classes, because this was
the only relevant source that provided
data for a similar patient population
(ie, patients undergoing TF and TA
grouped together). Now that the full
details of the PARTNER cohort A
quality of life study are available,2
we have imputed these EQ-5D utility608 The Journal of Thoracic and Cvalues into our analysis (Table 1).
TAVI was dominated by SAVR when
using these EQ-5D utility values ob-
served in both the TF and TA arms.
TF compared with SAVR had an
incremental cost-effectiveness ratio
of $67,934/quality-adjusted life year
(QALY) when the difference in utility
values at years 2 to 20 of the model
was assumed to be 0.09 in favor of TF.
The evidence on the long-term sur-
vival of patients undergoing TAVI is
not available. Therefore, in the model,
we directly used the mortality ob-
served in the PARTNER trial for the
first year and the mortality of the gen-
eral public for the subsequent years.
However, this approach does not im-
ply that the survivals predicted by
the model are comparable to those of
the general public as argued by Os-
nabrugge and Kappetein. There were
other mortalities caused by stroke,
myocardial infarction, and acute kid-
ney injury considered throughout the
time horizon. We believe this is a rea-
sonable approach to predict the sur-
vivals for the patient population. Of
note, this base-case analysis was also
supplemented by the scenario analy-
ses with different mortality assump-
tions. As suggested by Osnabrugge
and Kappetein, the use of survival
functions to fit patient-level data is an-
other approach. This approach is obvi-
ously conditional on the access to
patient-level data and is also subject
to criticism. If there was any mortality
benefit from TAVI observed at the end
of the trial, the use of fitted survival
functions is likely to enlarge the dif-
ference in favor of TAVI.3
Osnabrugge and Kappetein also
were concerned about some resource
use and cost inputs in the model. To
address these concerns, we updated
our 1-way sensitivity analyses
(Table 1). Increasing the cost of bal-
loon valvuloplasty improved the
cost-effectiveness of TAVI, whereas
changes in the length of hospital stay
after SAVR had no impact. At high
SAVR procedural costs or lowerardiovascular Surgery c February 2013TAVI valve costs, TAVI gained less
QALYs at lower costs compared
with SAVR. The short-term probabil-
ity of acute kidney injury was incor-
rectly listed in Table 1 of our
original article, and the correct value
of .011 was used in our model.
The trial-based economic evalua-
tion by the PARTNER investigators
used patient-level data to estimate
the cost-effectiveness of TAVR com-
pared with standard therapy from
a US perspective.4 Detailed costing
was performed at an individual level
using hospital-billing data. This is in
contrast to the estimation of costs in
our model, which were mainly based
on average costs of long-term compli-
cation health states and may account
for the difference in lifetime costs ob-
served (incremental cost of $79,837
and $31,029, respectively). Larger
values for incremental life-years
(LYs) and QALYs (1.6 LYs and 1.3
QALYs compared with 0.9 LYs and
0.6 QALYs in our analysis) can be ac-
counted for by the use of exponential
models for survival extrapolation and
a lower discount rate of 3% compared
with 5% used in our model. Conse-
quently, overall results were more
favorable in our analysis with a re-
ported incremental cost-effectiveness
ratio of $51,324/QALY compared
with $61,889/QALY in the trial-
based analysis.
A comparison of the results from our
cohort A analysis and that presented by
Reynolds5 at the TransCatheter Thera-
peutic conference is limited by the
fact that the analysis by Reynolds was
a trial-based approach using only 12
months follow-up and thus may not
have captured all of the long-term costs
and benefits ofTAVRandSAVR. Itwill
be important for Reynolds to model the
lifetime effects of these 2 comparators
to obtain more reliable estimates of
cost-effectiveness.
Despite extensive review by an
expert advisory panel and subsequent
approval by the Food and Drug
Administration, the appropriate use
TABLE 1. One-way sensitivity analysis of various model parameters
TAVI vs SAVR TAVI vs SM
PARTNER EQ-5D values
Base case (NYHA converted to
EQ-5D utilities)
Dominated $51,324/QALY
EQ-5D utilities from the TF arm Dominated* $46,701/QALYy
EQ-5D utilities from the TF arm
(assume 0.03 difference at 2 y)
$13,031,292/QALY NA
EQ-5D utilities from the TF arm
(assume 0.06 difference at 2 y)
$135,163/QALY NA
EQ-5D utilities from the TF arm
(assume 0.09 difference at 2 y)
$67,934/QALY NA
EQ-5D utilities from the TA arm Dominated NA
Cost of balloon valvuloplasty
Base case ($29,600) NA $51,324/QALY
$15,000 NA $75,473/QALY
$20,000 NA $67,203/QALY
$25,000 NA $58,933/QALY
$30,000 NA $50,662/QALY
$35,000 NA $42,392/QALY
$40,000 NA $34,121/QALY
Length of stay after SAVR
Base case (36 d) Dominated NA
10 d Dominated NA
15 d Dominated NA
20 d Dominated NA
25 d Dominated NA
30 d Dominated NA
35 d Dominated NA
40 d Dominated NA
Procedural cost of SAVR
Base case ($32,784) Dominated NA
$25,000 Dominated NA
$30,000 Dominated NA
$35,000 Dominated NA
$40,000 Dominated NA
$45,000 TAVI costs $1063 less at 0.102 less
QALYs
NA
$50,000 TAVI costs $6063 less at 0.102 less
QALYs
NA
Cost of TAVR valve
Base case ($39,796) Dominated $51,324/QALY
$15,000 TAVI costs $13,642 less at 0.102 less
QALYs
$10,310/QALY
$20,000 TAVI costs $8642 less at 0.102 less
QALYs
$18,580/QALY
$25,000 TAVI costs $3642 less at 0.102 less
QALYs
$26,851/QALY
$30,000 Dominated $35,121/QALY
$35,000 Dominated $43,391/QALY
$40,000 Dominated $51,662/QALY
$45,000 Dominated $59,932/QALY
NA,Not available;NYHA,NewYorkHeart Association; PARTNER, Placement of Aortic Transcatheter Valve;QALY,
quality-adjusted life year; SAVR, surgical aortic valve replacement; SM, standard management; TA, transapical;
TAVI, transcatheter aortic valve implantation; TF, transfemoral. *Difference in EQ-5D utility score at 1 year was
equal to 0.01 as reported by Reynolds et al.2 yUtilities values for TF placement in inoperable patients obtained
from Neyt and Van Brabandt.3
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The Journal of Thoracic and Cardiovascular Surgeof the SAPIEN (Edwards Lifescien-
ces, Irvine, Calif) heart valve for
high-risk operable patients remains
uncertain. Unfortunately, uncertainty
surrounding the benefits and risks of
TAVI largely affects estimates of the
incremental cost-effectiveness. Al-
though recently available evidence
has shed some light, uncertainty still
remains significant.
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